SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to strong community support and ongoing building efforts, including IRL initiatives and new product teases like KENDU SPICE. Community members express conviction and encourage others to join the movement, emphasizing KENDU's potential to become a major brand. Discussions also highlight the upcoming KENDU Games release and various merchandise offerings.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid speculation of a potential acquisition, especially after Pfizer's recent move in the obesity market, sparking discussions about Viking's value and potential suitors. Community members are debating the company's valuation, comparing its assets to competitors, and analyzing potential buyout scenarios. Discussions also include the impact of potential Medicare/Medicaid coverage on the obesity market and potential partnership.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending due to recent earnings, where revenue increased, and full-year outlook was raised, despite a mixed market reaction. The community is debating whether the current price reflects the company's long-term potential in the AI space, with discussions around profitability targets and potential market manipulation. Bullish sentiment remains as some highlight strong fundamentals, recent analyst upgrades, and future growth catalysts, while others express concern over the stock's performance relative to its sector.

Monero

Monero is gaining traction as community members emphasize its importance as a leading privacy coin, drawing comparisons to what Bitcoin was originally intended to be. Despite some exchanges delisting XMR, discussions highlight Monero's solid use case, adoption in certain markets, and potential for significant growth as privacy becomes more valued in the crypto space. The community believes Monero is undervalued and poised for a substantial move.

Dogelon Mars

Dogelon Mars is trending amidst mixed community sentiment, with some expressing frustration over price movement and unrealized gains, while others remain hopeful and accumulate more tokens. The community is closely watching for potential catalysts like a significant burn or metaverse integration, but some express concern over broken promises from the development team. General market volatility and influence from broader crypto trends are also being discussed.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

EOSE is trending as investors compare it to PLTR and IREN, anticipating a similar breakout. The company's recent collaboration and supply agreements are fueling optimism, with community members citing a large commercial pipeline. Discussions revolve around key resistance levels and potential for significant growth in the energy storage sector, particularly related to AI and hyperscalers.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as community members discuss its potential for a significant move, referencing its strong fundamentals and historical performance, while some traders point to technical indicators suggesting a possible breakout. Discussions also involve comparisons to other cryptocurrencies and speculation about a potential altcoin season. The community seems optimistic about Litecoin's long-term prospects and usage.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending amid reports of a potential breakup into two separate companies, focusing on sauces and condiments versus grocery products, which has sparked discussion about unlocking shareholder value. While some are skeptical, pointing to existing debt and margin concerns, others see an opportunity for strategic focus and growth, especially with the high dividend yield becoming more attractive amidst potential rate cuts. Community members are actively debating whether this split will truly benefit the stock or if it's simply rearranging a struggling business.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending amidst speculation surrounding the extension of ACA subsidies and the potential impact on the company's future profitability, further fueled by mixed earnings reports in the healthcare sector. The stock exhibits high volatility, with community members debating whether to buy, sell, or hold, based on their outlook for ACA and the company's 2026 profitability guidance. Some traders are closely watching technical indicators for potential entry or exit points, while others are highlighting large institutional ownership as a bullish sign.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp. is trending amid discussions around potential ACA subsidy extensions and the impact of a possible government shutdown on healthcare. Community members are weighing the implications of Trump's comments on healthcare and potential impacts on insurance companies, while also considering Centene's financial outlook and potential for growth in the sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low after the company announced a significant setback for its lead drug candidate, AK006.The biotech company revealed it would cease further clinical development of AK006 after its preclinical inhibitory effects failed to translate into clinical benefits for patients with chronic spontaneous urticaria (CSU).In the proof-of-concept trial, 34 adult patients with moderate-to-severe CSU refractory to antihistamines, with or without prior omalizumab exposure, were randomized 2:1 to receive AK006 or placebo.&nbsp;The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.&nbsp;The company will retain a small team of about 15 employees to explore strategic alternatives, ensure compliance, and oversee the wind-down of its phase 1 trial.Allakos ended the fourth quarter of 2024 with $81 million in cash and expects restructuring costs of $34–$38 million, primarily to be paid by mid-2025.&nbsp;The company estimates its cash reserves will decline to $35–$40 million by June 30, 2025.Following the announcement, several analysts adjusted their outlook on Allakos, according to The Fly.Piper Sandler downgraded the stock to ‘Neutral’ from ‘Overweight,’ slashing its price target to $0.30 from $7. The brokerage noted AK006 was Allakos’s sole asset, leaving the remaining valuation restricted to cash.JMP Securities downgraded Allakos to ‘Market Perform’ from ‘Outperform’.On Stocktwits, sentiment for Allakos shifted sharply to ‘bearish’ as disappointed retail investors voiced their concerns.&nbsp;<stembedurl>https://stocktwits.com/Majlo97/message/601635808</stembedurl><stembedurl>https://stocktwits.com/subieroo_wrx/message/601634053</stembedurl>Data showed declining interest in the stock, with a 4.6% drop in followers over the past year and a 44% reduction in message volume last week.<a href="https://stocktwits.com/symbol/ALLK">Allakos stock</a> has now lost 77% over the past 12 months, reflecting mounting challenges for the small-cap biotech as it faces an uncertain future.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Allakos Stock Craters To Record Low On Lead Drug Setback: Retail Hopes Fade

The disappointing results prompted Allakos to terminate AK006-related programs across all functions and implement a 75% workforce reduction.

Equity

Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm PR Newswire NEW YORK, Dec. 19, 2024 NEW YORK, Dec. 19, 2024...

Leerink Partnrs Research Analysts Lower Earnings Estimates for Allakos Inc. (NASDAQ:ALLK)

Allakos Inc. (NASDAQ:ALLK  Free Report)  Equities researchers at Leerink Partnrs decreased their FY2025 EPS estimates for shares of Allakos in a research report issued to clients and...

Short Interest in Allakos Inc. (NASDAQ:ALLK) Increases By 9.1%

Allakos Inc. (NASDAQ:ALLK  Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 29th, there was short interest totalling...

Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4

Restructuring Plan Aims to Extend Cash Runway Amid Clinical Development FocusRelated Stocks: ALLK...

Allakos says restructuring extends cash runway into mid-2026

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Allakos reports Q4 EPS (71c), consensus (47c)

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company ) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...

Commit To Buy Allakos At $1, Earn 17.9% Annualized Using Options

Investors eyeing a purchase of Allakos Inc (ALLK) shares, but cautious about paying the going market price of 1.48/share, might benefit from considering selling puts among the alternative...

Allakos Inc. (NASDAQ:ALLK) Given Average Rating of "Hold" by Analysts

Shares of Allakos Inc. (NASDAQ:ALLK  Get Free Report) have earned an average rating of Hold from the seven analysts that are currently covering the company, MarketBeat Ratings...

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Allakos Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

ALLK
Allakos Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALLK News

ALLKAllakos Inc